Skip to content

RealMove (Lung): Assessing Tumour Motion With Dynamic MRI

RealMove (Lung): Assessing Tumour Motion With Dynamic MRI

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06322329
Acronym
RealMove(lung)
Enrollment
150
Registered
2024-03-21
Start date
2024-03-15
Completion date
2036-03-17
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Tumor

Keywords

Radiotherapy, Motion management, Dynamic MRI

Brief summary

The study aims to develop an improved method to tailor the geometric safety margin when treating with stereotactic body radiotherapy (SBRT), to avoid tumour cells being missed during irradiation and to limit the exposure of normal tissues as much as possible. Dynamic magnetic resonance imaging (MRI) is assumed to represent the tumour motion during the respiratory cycle more realistically, compared to 4-dimensional computed tomography (4D CT), thanks to its high temporal resolution and the possibility to image the motion over a longer period of time. Patients receiving SBRT for a pulmonary target located below the level of the carina are included in the study, and the hypothesis will be tested through a comparison of the tumour amplitude measured with each modality. Furthermore, the predictive value of the image series acquired at treatment planning, for the motion patterns observed at each treatment fraction, will be evaluated through repeated 4D CBCT acquisitions.

Detailed description

In the current study, a 2D-cine MRI examination will be performed, in addition to the 4D CT examination that is standard for patients receiving radiotherapy for tumours in the thorax or abdomen. A subgroup of the study participants (referred to as the 4D CBCT subcohort) will also be required to perform a 4D CBCT examination at three treatment sessions. The main cohort consists of 95 subjects and the 4D CBCT subcohort of 55 subjects. The study does not involve any change in the treatment routine; rather, the study images are collected for retrospective analysis. Following each imaging session, the subject should fill out an anxiety questionnaire and their pulse will be measured, to give an indication of any anxiety which might influence the breathing pattern of the current session. Clinical follow-up will be performed retrospectively by reviewing the participants' medical records. Progress, health status and treatment-related toxicity will be evaluated, up to 10 years after completed treatment. The study objectives are: * To evaluate dynamic MRI for characterising the respiratory-related tumour motion, compared to the current standard modality of 4D CT. * To evaluate the variation in breathing motion at different times points. * To evaluate the clinical outcome.

Interventions

Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.

Sponsors

Uppsala University Hospital
CollaboratorOTHER
Region Stockholm
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Accepted for SBRT treatment of one or more caudally situated lung targets (NSCLC or metastases), i.e. below the carina. * Age ≥ 18 years * Adequate clinical condition to maintain immobilised position for at least 30 minutes * Adequate Swedish skills and cognitive function to understand study information and to fill in the questionnaire

Exclusion criteria

* Pregnancy or breastfeeding, or planned pregnancy or breastfeeding, during treatment * Contraindication for MRI examination * Otherwise incapable of participating in study

Design outcomes

Primary

MeasureTime frameDescription
Difference in amplitude of the tumour motion, as assessed by dynamic MRI and 4D CT, respectivelyOver 3-4 weeks: twice pre-treatment, and three times during treatmentThe two dynamic scans represent the tumour motion through different techniques. If the amplitude indicated by 4D CT is smaller than that indicated by dynamic MRI, the hypothesis is confirmed.
Difference in amplitude of the tumour motion, assessed at different times (using dynamic MRI and 4D CBCT)Over 3-4 weeks: twice pre-treatment, and three times during treatment4D CBCT images are acquired at each treatment session, in treatment position. These will assess the stability of the breathing patter through the treatment course.
Difference in the structure of the probability density function, assessed at different timesOver 3-4 weeks: twice pre-treatment, and three times during treatmentThe breathing pattern is represented by a probability density function, indicating the regularity of the motion. The stability of this pattern through the treatment course will be assessed.

Secondary

MeasureTime frameDescription
Progression-free survivalUp to 10 years after treatmentReview of medical records
Overall survivalUp to 10 years after treatmentReview of medical records
Grade ≥2 toxicity assessed by CTCAE v.5.0Up to 10 years after treatmentReview of medical records
Anxiety during examinations of tumour motionOver 3-4 weeks: twice pre-treatment, and three times during treatmentMeasured by a questionnaire

Countries

Sweden

Contacts

Primary ContactMattias Hedman, MD PhD
mattias.hedman@regionstockholm.se+46812370000
Backup ContactEva Onjukka, PhD
eva.onjukka@ki.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026